SCHEMBL2426698

SCHEMBL2426698

FC(F)(F)Oc1ccc(C2CCC[N]2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 1/20 0.45
NISCH Q9Y2I1 1/20 0.40
KDM1A O60341 1/20 0.39
RCOR1 Q9UKL0 1/20 0.39
SCN10A Q9Y5Y9 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
EPHX1 P07099 1/20 0.38
EPHX2 P34913 1/20 0.38
DHODH Q02127 1/20 0.36
SLC6A4 P31645 1/20 0.35
HTR2A P28223 1/20 0.35
GABBR2 O75899 1/20 0.35
GABBR1 Q9UBS5 1/20 0.35
FPR2 P25090 2/20 0.35
PROKR1 Q8TCW9 2/20 0.35
HRH3 Q9Y5N1 1/20 0.35
SCN9A Q15858 1/20 0.35
MMP2 P08253 2/20 0.35
MMP9 P14780 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2097724 0.85 SLC6A4 (0.38) GRIN2BNISCHKDM1ARCOR1EPHX1
SCHEMBL5536441 0.77 HTR2C (0.44) NISCHKDM1ARCOR1
SCHEMBL10379980 0.74 KDM1A (0.42) KDM1ASLC6A4HTR2A
SCHEMBL7295290 0.73 POLB (0.42) MEN1KMT2AMMP2MMP9MMP14
SCHEMBL5535778 0.73 GRIN2B (0.40) GRIN2BNISCHKDM1ASCN10AEPHX1
SCHEMBL2302374 0.72 L3MBTL1 (0.42) GRIN2BNISCHKDM1ARCOR1SCN10A
SCHEMBL4564168 0.72 L3MBTL1 (0.47) GRIN2BNISCHKDM1ARCOR1MEN1
SCHEMBL7724468 0.72 EPHX2 (0.48) KDM1ARCOR1SCN10AMEN1KMT2A
SCHEMBL5537503 0.71 CYP19A1 (0.36) NISCHKDM1AHTR2A
SCHEMBL8004698 0.71 ESR2 (0.41) KDM1ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9440958-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2016-09-13 US disclosed
US-20150025056-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION (US) 2015-01-22 US disclosed
US-8853243-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2014-10-07 US disclosed
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION 2011-09-15 US disclosed
US-7491724-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2009-02-17 US disclosed
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES MMP25, MMP14, MMP9 GRIN2B 3901/4885NISCH 2194/4885KDM1A 697/4885
US-20150025056-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES MMP25, MMP2, MMP14 GRIN2B 3868/4885NISCH 2540/4885KDM1A 493/4885
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases MMP25, MMP2, MMP14 GRIN2B 3868/4885NISCH 2540/4885KDM1A 493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.